Stock CRBU CARIBOU BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
2.12 USD -2.08% Intraday chart for Caribou Biosciences, Inc. -26.39% -63.00%
Jun. 04 US Equities Markets Close Mixed Monday as US Manufacturing Contracts MT
Jun. 04 HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
US Equities Markets Close Mixed Monday as US Manufacturing Contracts
MT
HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Gain Late Afternoon
MT
Sector Update: Health Care
MT
Top Midday Decliners
MT
Caribou Biosciences Shares Fall After Evercore ISI Downgrade on Post Clinical Trial Results
MT
Caribou Biosciences : CB-010 ANTLER Update ASCO 2024
PU
Caribou Biosciences : CB-012 AMpLify Study Trial Design ASCO 2024
PU
Top Premarket Decliners
MT
Evercore ISI Downgrades Caribou Biosciences to In-Line Rating With $3 Price Target
MT
Caribou Biosciences : Corporate Presentation May 2024
PU
Caribou Biosciences : KOL discussion of CB-010 ANTLER Phase 1 final trial data at ASCO
PU
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Caribou Biosciences, Inc. Presents Encouraging Clinical Data from CB-010 Antler Phase 1 Trial in Second-Line Lbcl Patients At the 2024 American Society of Clinical Oncology Annual Meeting
CI
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
AQ
Caribou Biosciences : Cas12a chRDNA in vivo editing ASGCT 2024
PU
Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating
MT
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Caribou Biosciences to Participate in Upcoming Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRBU Stock
  4. News Caribou Biosciences, Inc.